FiercePharma

Competition for Early-Line Biologic Use among Psoriasis Patients Intensifies as Humira Continues to Gain Ground on Enbrel

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that competition for early-line use of Amgen/Pfizer's Enbrel and ...
Business Wire

Enbrel and Humira Continue to Be Used as the Preferred First and Second Line Biologic Agents to Treat Rheumatoid Arthritis, but Orencia SC’s Usage Has Increased over the Last ...

EXTON, Pa.--(BUSINESS WIRE)--BioTrends Research Group, one of the world’s leading research and advisory firms for specialized biopharmaceutical issues, finds that there has been a slight increase in ...

Comparing 12 common rheumatoid arthritis prescriptions

SaveHealth reports on common rheumatoid arthritis medications, highlighting their effectiveness, side effects, and cost ...
BioWorld

Interchangeable would be game changer for Humira competition

"Interchangeability would change the game for Humira," Mohan said. It also would be a game-changer for biosimilars hoping to compete in the space, as it could give the interchangeable the advantage of ...
The American Journal of Managed Care

Alberta, Canada, Begins Mandating Switches From Originator to Biosimilar Humira

Alberta, Canada becomes the latest province to begin switching patients from originator adalimumab (Humira) to biosimilar versions as part of its Biosimilars Initiative. Alberta, Canada has expanded ...